Open Orphan PLC chief financial officer Stephen Pinkerton speaks to Proactive about his recent elevation to the role and the upcoming change of name to hVIVO.
Open Orphan has recently seen a surge in orders using human-challenge clinical trials for infectious and respiratory diseases.
Pinkerton says that there are still “lots of opportunities to be had around the business” and highlights the areas of asthma and malaria models.
#proactiveinvestors #OpenOrphan #hVIVO
